

QuaCell® CHO-K1Q Cell line

QuaCell® CHO-K1Q Cell line is from ECACC, The QuaCell R&D team used patent technology to domesticate and screen, without genetic modification, and the main characteristics are the same as CHO-K1.



Product advantages:


- High Lac, NH₄ & Osmo resistance
- Platform process, providing complete solutions to speed up R&D process
- High titer, the average IgG is more than 4.0 g/L, and the highest is 14 g/L
- Clear source, providing complete IND&BLA document support
- FTO, flexible global commercial license

Data Presentation

High tolerance


When cultured in a standard commercial basal medium, CHO-K1Q cells exhibited a reduced rate of viable cell density (VCD) decline compared to CHO-K1 cells. Furthermore, under conditions of heightened osmolality (400 mOsm/kg), elevated lactate levels (2.5 g/L), and increased ammonium concentrations (7.5 mM), CHO-K1Q cells demonstrated the ability to maintain normal VCD. These findings underscore the enhanced resilience of CHO-K1Q cells to diverse culture conditions, highlighting their potential suitability for robust biotechnological applications

[The VCD of CHO-K1 and CHO-K1Q during batch cultivation at different conditions]




High adaptability

Through the examination of CHO-K1Q cell growth across thirteen commonly utilized commercially available media, it was determined that the CHO-K1Q cell line demonstrates compatibility with nearly all media accessible in the market. Moreover, notable adaptation and favorable growth were observed when utilizing QuaCell's media, suggesting its efficacy and suitability for sustaining CHO-K1Q cell cultures.



Wide-ranging applications & High yield

CHO-K1Q cell line currently enjoys utilization by over 100 companies across more than 200 projects. Notably, over 20 of these projects have received Investigational New Drug (IND) approvals, demonstrating regulatory compliance and efficacy. Additionally, successful instances of dual-reporting in both Chinese and American regulatory frameworks have been documented. The versatility of the CHO-K1Q cell line extends to a wide array of expression products, encompassing monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and recombinant proteins. Across numerous projects, the average expression level exceeds 4 g/L, with peak yields reaching as high as 14 g/L. These findings underscore the robust performance and applicability of the CHO-K1Q cell line in biotechnological endeavors.



Supporting documents

Traceability	Development	License	Support
Purchase proof	Experimental records	Original cell license	Supporting series of products
Customs certificate	Test Report	Quacell license	Platform technology
Shipping records	Quality System	Global commercial application	IND&BLA document support

Ordering Information

Product	Cat.No.	Storage	Amount	Application
QuaCell® CHO K1Q Cell line	A13101	LN2	1.5x10 ⁷ cells/vial	Production of protein